2. Signaling Pathways
  3. GPCR/G Protein
  4. GCGR
  5. GCGR Antagonist

GCGR Antagonist

GCGR Antagonists (25):

Cat. No. Product Name Effect Purity
  • HY-116854
    NNC 92-1687
    		Antagonist 98.74%
    NNC 92-1687 is a non-peptide competitive human glucagon receptor antagonist (IC50=20 μM; Ki=9.1 μM). NNC 92-1687 can be used in the research of type 2 diabetes.
  • HY-50663
    MK 0893
    		Antagonist 99.86%
    MK 0893 is a potent and selective glucagon receptor antagonist with an IC50 of 6.6 nM.
  • HY-101116
    GLP-1R Antagonist 1
    		Antagonist 99.84%
    GLP-1R Antagonist 1 (compound 5d) is an orally active, CNS penetrant and non-competitive antagonist of glucagon-like peptide 1 receptor (GLP-1R), with an IC50 of 650 nM.
  • HY-19904
    Adomeglivant
    		Antagonist 99.63%
    Adomeglivant (LY2409021) is a potent, selective glucagon receptor (GluR) allosteric antagonist. Adomeglivant is widely used in the research for type 2 diabetes mellitus.
  • HY-P1141
    GLP-1(9-36)amide
    		Antagonist 99.78%
    GLP-1(9-36)amide is a major metabolite of glucagon-like peptide-1-(7-36) amide formed by the enzyme dipeptidyl peptidase-4 (DPP-4). GLP-1(9-36)amide acts as an antagonist to the human pancreatic GLP-1 receptor.
  • HY-19947
    PF-06291874
    		Antagonist 99.18%
    PF-06291874 is a highly potent, non-peptide and orally active glucagon receptor antagonist. PF-06291874 is under the study for type 2 diabetes mellitus (T2DM).
  • HY-12525
    LGD-6972
    		Antagonist ≥98.0%
    LGD-6972 is a selective and orally active glucagon receptor antagonist. LGD-6972 has the potential for type 2 diabetes research.
  • HY-103547
    L-168049
    		Antagonist 99.93%
    L-168049 is a potent, selective, orally active and non-competitive glucagon receptor antagonist with IC50s of 3.7 nM, 63 nM, and 60 nM for human, murine, and canine glucagon receptors, respectively.
  • HY-50159
    Glucagon receptor antagonists-3
    		Antagonist 98.52%
    Glucagon receptor antagonists-3 is a highly potent glucagon receptor antagonist.
  • HY-50158
    Glucagon receptor antagonists-2
    		Antagonist 99.23%
    Glucagon receptor antagonists-2 is a highly potent glucagon receptor antagonist.
  • HY-P99383
    Volagidemab
    		Antagonist 98.43%
    Volagidemab is an antagonistic glucagon receptor (GCGR) monoclonal antibody (mAb). Volagidemab can be used in the research of type 1 diabetes (T1D).
  • HY-P1143A
    [Des-His1,Glu9]-Glucagon amide TFA
    		Antagonist 99.62%
    [Des-His1,Glu9]-Glucagon amide TFA is a potent and peptide antagonist of the glucagon receptor, with a pA2 of 7.2. [Des-His1,Glu9]-Glucagon amide TFA is potentially useful in the study of the pathogenesis of diabetes.
  • HY-P1141A
    GLP-1(9-36)amide TFA
    		Antagonist 98.00%
    GLP-1(9-36)amide TFA is a major metabolite of glucagon-like peptide-1-(7-36) amide formed by the enzyme dipeptidyl peptidase-4 (DPP-4). GLP-1(9-36)amide TFA acts as an antagonist to the human pancreatic GLP-1 receptor.
  • HY-148844
    GCGR antagonist 2
    		Antagonist 99.76%
    GCGR antagonist 2, a Furan-2-carbohydrazide, is an orally active glucagon receptor antagonist. GCGR antagonist 2 binds to hGluR with an Kd value of 2.3 nM, and inhibits rat receptor with an IC50 value of 0.43 nM. GCGR antagonist 2 inhibits glucagon-stimulated glycogenolysis.
  • HY-119739
    Skyrin
    		Antagonist
    Skyrin is an anthraquinone compound that can be isolated from almond fruit. Skyrin is a receptor-selective glucagon antagonist. Skyrin can inhibit the growth of tumor cells.
  • HY-10036
    Glucagon receptor antagonists-1
    		Antagonist 98.65%
    Glucagon receptor antagonists-1 is a highly potent glucagon receptor antagonist.
  • HY-P2497
    Exendin (5-39)
    		Antagonist 99.81%
    Exendin (5-39) is a potent glucagon-like peptide 1 (GLP-1) receptor antagonist. Exendin (5-39) improves memory impairment in β-amyloid protein-treated rats.
  • HY-128781
    Glucagon receptor antagonists-5
    		Antagonist
    Glucagon receptor antagonists-5 (compound 13K) is a potent and orally bioavailable indazole-based glucagon receptor antagonist (Ki=32 nM). Glucagon receptor antagonists-5 has potential for the treatment of type 2 diabetes mellitus (T2DM).
  • HY-P3542
    Des His1, Glu8 Exendin-4
    		Antagonist
    Des His1, Glu8 Exendin-4 is a potent glucagon-like peptide-1 receptor (GLP-1-R) antagonist. Des His1, Glu8 Exendin-4 improves glucose homeostasis by regulating both insulin secretion and glucose production. Des His1, Glu8 Exendin-4 can be used for the research of type 2 diabetic and gastrointestinal.
  • HY-P1143
    [Des-His1,Glu9]-Glucagon amide
    		Antagonist
    [Des-His1,Glu9]-Glucagon amide is a potent and peptide antagonist of the glucagon receptor, with a pA2 of 7.2. [Des-His1,Glu9]-Glucagon amide is potentially useful in the study of the pathogenesis of diabetes.